Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes
Jonker, Jacqueline T × Wang, Yanan de Haan, Willeke Diamant, Michaela Rijzewijk, Luuk J van der Meer, Rutger W Lamb, Hildo J Tamsma, Jouke T de Roos, Albert Romijn, Johannes A Rensen, Patrick C N Smit, Johannes W A #
American Diabetes Association
Diabetes Care vol:33 issue:7 pages:1625-8
Thiazolidinediones reduce hepatic steatosis and increase HDL cholesterol levels. In mice with human-like lipoprotein metabolism (APOE*3-Leiden.CETP transgenic mice), a decrease in hepatic triglyceride content is associated with a decrease in plasma cholesteryl ester transfer protein (CETP) mass and an increase in HDL levels. Therefore, the aim of the present study was to assess the effects of pioglitazone on CETP mass in patients with type 2 diabetes.